A 10‑year retrospective study on a population‑based cervical cancer screening programme in Nigeria
Main Article Content
Abstract
BACKGROUND: Human papillomavirus (HPV) is the main cause of cervical cancer, and about 80% of women will be infected at least once in their life time. Cervical cancer is the fourth most common cancer in women and the second highest cause of cancer deaths. Persistent HPV infection progresses to cancer over several years, and during this period, pre‑cancerous lesions can be detected by screening. Visual inspection under acetic acid (VIA) is an easy safe, affordable and effective test in cervical cancer screening in resource‑poor countries like Nigeria.
AIM: The aim of the study is to determine the proportion of women with VIA‑positive findings and the associated factors among those screened for cervical cancer in a screening programme between 2008 and 2017.
METHODS: This is a retrospective study using the database of women who presented for breast and cervical cancer screening by the Akwa‑Ibom State branch of the Medical Women’s Association of Nigeria between 2008 and 2017. A structured questionnaire was used to abstract data from the records of the attendees at the cancer screening sessions in the years indicated. There are many factors that discourage women from screening for cervical cancer. Some authors cite embarrassment, low perception of cancer risk, physician gender preference, lack of spousal support; high cost; belief that cancer is a death sentence, and societal discrimination.
RESULTS: A total of 2203 women were screened for cervical cancer between 2008 and 2017. The mean age was 40.2 years. Only 284 (12.9%) women had been previously screened for cervical cancer, and majority of these were screened over 2 years prior. The mean age at sexual debut was 19.4 years, those who had used contraceptive pills in the past were 639 (29.0%) while 124 (5.6%) used it currently.
Forty‑four (2.0%) of the screened women had VIA‑positive lesions, and 1.6% had lesions suspicious for cancer. On bivariate analysis, age, marital status, age at sexual debut, number of pregnancies and previous use of oral contraceptive pills were significantly associated with findings on VIA.
CONCLUSION: This study found VIA‑positive findings in a small proportion of the women screened. A follow‑up of the definitive diagnosis and treatment of the VIA‑positive women is strongly recommended. Efforts should be made to provide early comprehensive sex education and screening to detect early lesions to reduce morbidity and mortality from cervical cancer in the population.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
World Health Organization. Cervical Cancer. World Health Organisation Fact Sheet; 2019. Available from: https://www.who.int/westernpacific/health-topics/cervical-cancer. [Last accessed on 2020 Sep 28].
WHO Technical Guidance and Specifications of Medical Devices for Screening and Treatment of Precancerous Lesions in the Prevention of Cervical Cancer. Geneva: World Health Organisation, Liscence: CC BY-NC-SA 30 IGO; 2020.
International Agency for Research on cancer. Population Fact Sheet. World Health Organisation; 2018. Available from: https://gco.iarc.fr/today/data/factsheets/populations/566-nigeria-factsheets.pdf. [Last accessed on 2020 Sep 28].
Senkomago V, Duran D, Loharikar A, Hyde TB, Markowitz LE, Unger ER, et al. CDC Activities for Improving Implementation of Human Papillomavirus Vaccination, Cervical Cancer Screening, and Surveillance Worldwide - Emerging Infectious Diseases Journal - CDC. Vol. 23, December, 2017. Available from: Available from: Available from: https://wwwnc.cdc.gov/eid/article/23/13/17-0603_article. [Last accessed on 2020 Sep 28].
World Health Organization. Human papillomavirus (HPV) and cervical cancer. World Health Organisation fact sheet. 2019. Available from: https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer. [Last accessed on 2020 Sep 28].
Oguntayo O, Zayyan M, Kolawole A, Adewuyi S, Ismail H, Koledade K. Cancer of the cervix in Zaria, Northern Nigeria. Ecancermedicalscience 2011;5:219.
Idowu A, Olowookere SA, Fagbemi AT, Ogunlaja OA. Determinants of cervical cancer screening uptake among women in Ilorin, North Central Nigeria: A community-based study. J Cancer Epidemiol 2016;2016:6469240.
Akwaowo CD, Vanni T. Cervical cancer screening: Barriers to access and potential solutions for Nigeria. Clin Biomed Res 2015;35:5-13.
MWAN AIS. A History of Medical Women’s Association of Nigeria, Akwa Ibom State. Mwan Newsl 2020 2020;3:16-7.
IARC, WHO. Testing and Reporting the Results of Visual Inspection with 5% Acetic Acid (VIA). Practical Manual on Visual Screening for Cervical Neoplasia. Available from: https://screening.iarc.fr/viavilichap2.php?lang=1. [Last accessed on 2021 Apr 29].
Cervical Cancer Statistics | Key Facts about Cervical Cancer. Available from: https://www.cancer.org/cancer/cervicalcancer/about/key-statistics.html. [Last accessed on 2020 Nov 08].
World Health Organization, World Health Organization, Reproductive Health and Research. Comprehensive Cervical Cancer
Control: A Guide to Essential Practice. 2014 Available from: http://apps.who.int/iris/bitstream/10665/144785/1/9789241548953_
eng.pdf?ua=1. [Last accessed on 2020 Nov 08].
The American Cancer Society Guidelines for the Prevention and Early Detection of Cervical Cancer. Available from: https://www.
cancer.org/cancer/cervical-cancer/detection-diagnosis-staging/cervical-cancer-screening-guidelines.html. [Last accessed on 2020
Nov 08].
Okunowo AA, Smith-Okonu ST. Cervical cancer screening among urban Women in Lagos, Nigeria: Focus on barriers and motivators
for screening. Niger J Gen Pract 2020;18:10.
Yahya A, Mande A. Awareness and knowledge of cervical cancer and its screening methods among women attending primary
healthcare centers in Zaria, North-Western, Nigeria. Trop J Obstet Gynaecol 2019;36:271-6.
Dodo AM, Sykes P, Powell C. Exploring the barriers to breast and cervical cancer screening in Nigeria: A narrative review. Afr
J Reprod Health 2016;20:89-98.
Huy NVQ, Tam LM, Tram NVQ, Thuan DC, Vinh TQ, Thanh CN,et al. The value of visual inspection with acetic acid and Pap smear in cervical cancer screening program in low resource settings - A population-based study. Gynecol Oncol Rep 2018;24:18-20.
Poli UR, Bidinger PD, Gowrishankar S. Visual inspection with acetic acid (VIA) screening program: 7 years experience in early
detection of cervical cancer and pre-cancers in rural South India. Indian J Community Med 2015;40:203-7.
Sankaranarayanan R, Basu P, Wesley RS, Mahe C, Keita N, Mbalawa CC, et al. Accuracy of visual screening for cervical neoplasia: Results from an IARC multicentre study in India and Africa. Int J Cancer 2004;110:907-13.
Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J,et al. Estimates of incidence and mortality of cervical cancer in
: A worldwide analysis. Lancet Glob Health 2020;8:e191-203.
El Ibrahimi S, Pinheiro PS. The effect of marriage on stage at diagnosis and survival in women with cervical cancer. Psychooncology 2017;26:704-10.
Patel MK, Patel DA, Lu M, Elshaikh MA, Munkarah A, Movsas B. Impact of marital status on survival among women with invasive
cervical cancer: Analysis of population-based surveillance, epidemiology, and end results data. J Low Genit Tract Dis 2010;14:329-38.
Magnusson BM, Crandall A, Evans K. Early sexual debut and risky sex in young adults: The role of low self-control. BMC Public
Health 2019;19:1483.
Durowade KA, Babatunde OA, Omokanye LO, Elegbede OE, Ayodele LM, Adewoye KR, et al. Early sexual debut: Prevalence and risk factors among secondary school students in Ido-ekiti, Ekiti state, South-West Nigeria. Afr Health Sci 2017;17:614-22.
Yaya S, Bishwajit G. Age at first sexual intercourse and multiple sexual partnerships among women in Nigeria: A cross-sectional
analysis. Front Med (Lausanne) 2018;5:171.
Fagbamigbe AF, Idemudia E. Diversities in timing of sexual debut among Nigerian youths aged 15-24 years: Parametric and non-parametric survival analysis approach. Afr Health Sci 2017;17:39-51.
Louie KS, de Sanjose S, Diaz M, Castellsagué X, Herrero R, Meijer CJ, et al. Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. Br J Cancer 2009;100:1191-7.
Natphopsuk S, Settheetham-Ishida W, Sinawat S, Pientong C, Yuenyao P, Ishida T. Risk factors for cervical cancer in northeastern
Thailand: Detailed analyses of sexual and smoking behavior. Asian Pac J Cancer Prev 2012;13:5489-95.
Muñoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS,et al. Role of parity and human papillomavirus in cervical cancer:
The IARC multicentric case-control study. Lancet 2002;359:1093-101.
World Health Organization, editor. WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer
Prevention. Geneva: World Health Organization; 2013. p. 40.
Sogukpinar N, Saydam BK, Can HO, Hadimli A, Bozkurt OD, Yucel U, et al. Assessment of cervical cancer risk in women between 15 and 49 years of age: Case of Izmir. Asian Pac J Cancer Prev 2013;14:2119-25.
Hellberg D. Sex steroids and cervical cancer. Anticancer Res 2012;32:3045-54.
Delvenne P, Herman L, Kholod N, Caberg JH, Herfs M, Boniver J, et al. Role of hormone cofactors in the human papillomavirus-induced carcinogenesis of the uterine cervix. Mol Cell Endocrinol 2007;264:1-5.
Jensen KE, Schmiedel S, Norrild B, Frederiksen K, Iftner T, Kjaer SK. Parity as a cofactor for high-grade cervical disease among women with persistent human papillomavirus infection: A 13-year follow-up. Br J Cancer 2013;108:234-9.
Dyer O. WHO links long term pill use to cervical cancer. BMJ 2002;324:808.
American Cancer Society. Cervical Cancer Risk Factors | Risk Factors for Cervical Cancer. Available from: https://www.cancer.org/cancer/cervical-cancer/causes-risks-prevention/risk-factors.html. [Last accessed on 2020 Nov 09].
Oral Contraceptives (Birth Control Pills) and Cancer Risk National Cancer Institute. 2018. Available from: https://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/oral-contraceptives-fact-sheet. [Last accessed on 2020 Nov 09].
Abasiattai AM, Utuk MN, Ojeh SO, Eyo UE. Combined oral contraceptive pills: Profile of acceptors in a tertiary hospital in South-South Nigeria. Niger Med J. 2011;52:19-23.
Isa B, Ibrahim S, Kullima A, Bako B. Awareness and utilization of emergency contraception among female undergraduates in a Nigerian University. Trop J Obstet Gynaecol 2016;33:196.
Sugawara Y, Tsuji I, Mizoue T, Inoue M, Sawada N, Matsuo K,et al. Cigarette smoking and cervical cancer risk: An evaluation based on a systematic review and meta-analysis among Japanese women. Jpn J Clin Oncol 2019;49:77-86.
Roura E, Castellsagué X, Pawlita M, Travier N, Waterboer T, Margall N, et al. Smoking as a major risk factor for cervical cancer and pre-cancer: Results from the EPIC cohort. Int J Cancer 2014;135:453-66.
Tolstrup J, Munk C, Thomsen BL, Svare E, van den Brule AJ, Grønbaek M, et al. The role of smoking and alcohol intake in the development of high-grade squamous intraepithelial lesions among high-risk HPV-positive women. Acta Obstet Gynecol Scand 2006;85:1114-9.